Remus Pharmaceuticals H1-FY27 Earnings Highlights and Growth Roadmap
Remus Pharmaceuticals Ltd 路 Transcript 路 06 Nov 2026, 7:10 pm
Remus Pharmaceuticals H1-FY27 Earnings Highlights and Growth Roadmap For H1-FY27, Remus Pharmaceuticals posted consolidated revenue of INR 614.12 crores (up 53% YoY), EBITDA of INR 29.93 crores (margin 5%), and PAT of INR 24.66 crores (up 14% YoY). Standalone revenue rose 32% YoY to INR 62 crores with a 35% EBITDA margin and INR 19 crores PAT (up 57% YoY). The Board approved an interim dividend of INR 1 per share. Management targets higher H2 growth, driven by Latin American expansion, GLP-1 (Semaglutide) commercialization, biosimilars, and expected migration to the main board.
Original exchange filing (PDF)
More announcements from Remus Pharmaceuticals Ltd
- Remus Pharmaceuticals Limited has informed the Exchange about Audio Recording 路 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Investor Presentation 路 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange regarding a media release dated November 03, 2026 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Interim Dividend is 07-Nov-2026. 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2026, declared Interim Dividend of Rs. 1.00 per equity share. 路 03 Nov 2026
- Remus Pharmaceuticals Limited has submitted to the Exchange Outcome of Board Meeting held on November 03, 2026 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Schedule of meet 路 29 Oct 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Dividend/Other business. 路 03 Nov 2026
